659 filings
Page 15 of 33
6-K
el6y dqcgw55ju
31 Jul 18
Quarterly report for entities subject to Listing Rule 4.7B
12:00am
6-K
fas3oy9b1tk9l1closx
3 Jul 18
Current report (foreign)
12:00am
6-K
e25g30xi
20 Jun 18
Current report (foreign)
12:00am
6-K
3b2og0s esfymku7
5 Jun 18
Immutep Presentations at Asco
12:00am
6-K
xmhg8m
31 May 18
Current report (foreign)
6:13am
6-K
6wpj8
30 May 18
Current report (foreign)
6:12am
6-K
humzkqslgpf2qpr
18 May 18
Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast
12:00am
6-K
rk2v752w
7 May 18
Immutep to Present at 2018 Asco Annual Meeting
10:14am
6-K
2zi2eyujnxsyp64c5yhv
26 Apr 18
Quarterly report for entities subject to Listing Rule 4.7B
12:00am
6-K
2xwr5 356sg
13 Apr 18
Current report (foreign)
12:00am
6-K
oqzbcf9
13 Apr 18
Immutep Completes $6.31 Million Share Purchase Plan; Raises Total of $13.16 Million
12:00am
6-K
doi4nvvtje xwwpr4
4 Apr 18
Current report (foreign)
12:00am
6-K
uzzy1jr3lloie14
23 Mar 18
Current report (foreign)
12:00am
6-K
vt5qsok3lxr e33
20 Mar 18
Current report (foreign)
12:00am
6-K
ruqsupmucdn3npzs3o
16 Mar 18
Current report (foreign)
12:00am
6-K
if6e7 71szrz1
16 Mar 18
Current report (foreign)
12:00am
6-K
ltbfya4xa 2tn0whc5
13 Mar 18
Immutep Enters into Clinical Trial Collaboration and Supply Agreement with MSD
12:00am
6-K
yd41ivaw8r coz75dcu1
7 Mar 18
Immutep Announces United States Patent Grant for IMP701 Antibody
12:00am
6-K
42rt0eyqbajmxjk
6 Mar 18
Immutep receives A$686,704 R&D Tax Incentive
12:00am
6-K
c5zfxdvuttwx43f7cq3g
23 Feb 18
Current report (foreign)
12:00am